Vanguard Capital Management’s Benitec Biopharma BNTC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.4M Buy
1,035,637
+81,104
+8% +$991K ﹤0.01% 2730
2026
Q2
$12.8M Buy
954,533
+22,977
+2% +$273K ﹤0.01% 2692
2026
Q1
$9.9M Buy
+931,556
New +$10.8M ﹤0.01% 2732

Other funds holding BNTC

Vanguard Capital Management's BNTC Position: Q3 2026 in Review

Vanguard Capital Management increased its Benitec Biopharma (BNTC) stake by 8.5% in Q3 2026, buying an estimated $991K and bringing the position to 1,035,637 shares worth $10.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2730.

Vanguard Capital Management first reported a position in BNTC in Q1 2026 and has held it in 3 quarters since. The position peaked at $12.8M in Q2 2026. 91 funds tracked by Wall St. Rank hold BNTC as of Q3 2026.

  • Vanguard Capital Management held 1,035,637 shares of Benitec Biopharma worth $10.4M as of Q3 2026.
  • Vanguard Capital Management bought 81,104 Benitec Biopharma shares in Q3 2026, an estimated $991K.
  • Benitec Biopharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2730 holding.
  • Vanguard Capital Management first reported a position in Benitec Biopharma in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Benitec Biopharma position peaked at $12.8M in Q2 2026.
  • 91 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.